Virus therapy and immunotherapy for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of an oncolytic virus (a virus that attacks cancer cells) and a PD-1 inhibitor (an immunotherapy drug) for people with advanced pancreatic cancer that has not responded to at least two prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced pancreatic cancer that has spread or cannot be removed by surgery.
- You have tried at least two types of chemotherapy, or you cannot or choose not to have standard treatment.
- You are between 18 and 80 years old.
- You are in generally good health (able to care for yourself and up and about more than 50% of waking hours).
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an oncolytic virus (a virus that targets cancer cells), an immunotherapy drug (anti-PD1), and chemotherapy given before surgery for people with borderline resectable or locally advanced pancreatic cancer. The goal is to see if this approach can shrink the tumor enough to make surgery more successful.
This trial tests a new drug, VRT106, combined with chemotherapy for people with advanced pancreatic cancer that has not been treated before. The goal is to see if this combination helps shrink tumors or slow the cancer's growth.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This trial tests two different vaccines (GVAX and a mKRAS vaccine) given before and after surgery for pancreatic cancer. Both vaccines are combined with immunotherapy drugs to help your immune system fight the cancer. The goal is to see which vaccine works better and is safe for patients whose tumors can be removed.
This trial tests a new drug called VRT106 combined with chemotherapy for people with pancreatic cancer that can be surgically removed. The goal is to see if the combination works better than standard treatment alone.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.